Weight management
0Pfizer has announced it will “discontinue” the development of a weight loss pill amid “potential drug-induced liver injury”, less than two years after it decided “not [to] advance” a previous version.
0The pharmacy, medicine and advertising regulators have joined forces to warn pharmacies not to advertise weight loss drugs via social media, adding that pharmacies can still break the rules without naming a POM.
0A new study has revealed that the use of GLP-1RAs such as semaglutide are “not associated” with an increased risk of suicidality among patients with type 2 diabetes.
0Consultation numbers for a pharmacy service provider’s weight management service have grown “exponentially” in the last year, C+D has learned.
0The National Institute for Health and Care Excellence (NICE) has proposed that people with long-term conditions – including obstructive sleep apnoea, schizophrenia and learning disabilities – are weighed annually.
0The Danish drugmaker has launched a “direct-to-patient” pharmacy, offering "all dose strengths of Wegovy at a reduced cost”.
2In the first month of its updated guidance, the pharmacy regulator has already referred three individuals for fitness-to-practise (FtP) investigations for concerns around weight management drugs, C+D has learned.
5The health secretary has deemed Boots weight loss safeguards “totally unacceptable” after a new Dispatches documentary found that the pharmacy provided a 16-year-old with Wegovy against its own policy.
0A pharmacy has warned that that 16-24-year-olds are more likely to consider weight loss injections than older generations – in part due to the “unique pressures faced by Gen Z”.
0The CCA’s CEO Malcolm Harrison sat down with C+D and shared his thoughts on everything from funding to weight loss drugs. Here’s what he had to say...